Small Molecule Toxin Inhibitors for Snakebite Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current snakebite treatments, such as antivenoms, have limited efficacy against envenoming by different snake species due to specificity towards toxins in the venoms used in their manufacture, and they are costly, have poor dose efficacy, and require cold chain storage, making them suboptimal for rural areas where snakebite victims often delay seeking medical care.
Innovation Solution
Development of novel combinations of rationally selected small molecule toxin inhibitors, specifically combining snake venom metalloproteinase inhibitors like marimastat and DMPS with a phospholipase inhibitor like varespladib, to create therapeutic mixtures capable of neutralizing distinct pathogenic toxins found in geographically diverse viper venoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antivenoms are used for snakebite treatment, then specific toxin neutralization is achieved, but efficacy is limited against different snake species and cost is high
Solution Approach 1:
The patent develops a panel of small molecule inhibitors that can neutralize multiple toxin types across different snake species. Instead of species-specific antivenoms, the invention creates a universal treatment approach where a single panel of inhibitors (including metalloproteinase inhibitors like marimastat and DMPS, and phospholipase A2 inhibitors like varespladib) can effectively treat envenoming from various viper species, achieving cross-species efficacy without requiring species identification
Solution Approach 2:
The patent segments the venom toxin profile into distinct functional classes (metalloproteinases and phospholipase A2) and selects inhibitors that target each class specifically. This segmentation allows for a modular approach where individual inhibitors can be combined to create a comprehensive neutralization panel that addresses the full spectrum of viper toxins, improving both reliability and adaptability
2Reliability
If antivenoms are administered, then toxin neutralization occurs, but adverse reactions and poor dose efficacy occur
Solution Approach 1:
The patent replaces expensive, complex animal-derived antivenoms with affordable synthetic small molecule inhibitors. These small molecule drugs (such as marimastat, DMPS, and varespladib) are chemically synthesized, do not require cold chain storage, and can be administered orally or intravenously, eliminating the need for expensive infrastructure while maintaining effective toxin neutralization
Solution Approach 2:
The patent changes the fundamental parameters of the treatment approach by switching from protein-based antivenoms to small molecule inhibitors. This parameter change results in drugs with better pharmacokinetic properties, lower cost, no adverse reactions, and no cold chain requirements, while maintaining the ability to neutralize toxins effectively
3Reliability
If antivenoms are stored and transported, then treatment is available, but cold chain requirements increase complexity and cost
Solution Approach 1:
The patent replaces expensive, cold-chain-dependent antivenoms with stable small molecule inhibitors that do not require special storage conditions. These small molecule drugs can be stored at room temperature, eliminating the need for expensive cold chain infrastructure in rural areas, while still providing reliable treatment availability
4Ease of operation
If delay in seeking medical care occurs, then rural access is improved, but treatment efficacy is reduced
Solution Approach 1:
The patent enables self-service treatment by developing oral small molecule inhibitors that can be administered by the patient themselves without requiring clinical infrastructure. The drugs can be taken orally at home, eliminating the need for hospital visits and allowing patients to receive treatment immediately after the bite, regardless of their location
Solution Approach 2:
The patent allows for preliminary action by enabling patients to self-administer treatment immediately after the bite occurs, before reaching healthcare facilities. The oral formulation can be taken right away, providing immediate toxin neutralization while the patient is still at the scene of the bite, rather than waiting for transport to a hospital
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described therapeutic combinations of small molecule toxin inhibitors demonstrate enhanced efficacy over single drugs in preclinical models, offering broad-spectrum protection against snakebite envenoming and potential as generic therapies for treating viper snakebites.
Implementation Method 1
combining these drugs with a previously identified phospholipase inhibitor to generate two therapeutic small molecule mixtures capable of neutralizing distinct pathogenic toxins found in the venoms
Implementation Method 2
Two treatments targeting distinct toxin families were then combined to generate a dual-drug mixture that provided enhanced protection against venom lethality in a preclinical model
Data Source
AI summary
The disclosure herein are materials and methods for the treatment of snake bite. Aspects of the disclosure includes pharmaceutical compositions, and kits, both of which may be of use in the treatment of snake bite.